160 related articles for article (PubMed ID: 20334564)
1. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.
Rowley CF; Boutwell CL; Lee EJ; MacLeod IJ; Ribaudo HJ; Essex M; Lockman S
AIDS Res Hum Retroviruses; 2010 Mar; 26(3):293-300. PubMed ID: 20334564
[TBL] [Abstract][Full Text] [Related]
2. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
MacLeod IJ; Rowley CF; Thior I; Wester C; Makhema J; Essex M; Lockman S
J Clin Virol; 2010 Jul; 48(3):162-7. PubMed ID: 20427228
[TBL] [Abstract][Full Text] [Related]
3. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
Persaud D; Bedri A; Ziemniak C; Moorthy A; Gudetta B; Abashawl A; Mengistu Y; Omer SB; Isehak A; Kumbi S; Adamu R; Lulseged S; Ashworth R; Hassen E; Ruff A;
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):823-9. PubMed ID: 21241214
[TBL] [Abstract][Full Text] [Related]
4. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
Palmer S; Boltz V; Martinson N; Maldarelli F; Gray G; McIntyre J; Mellors J; Morris L; Coffin J
Proc Natl Acad Sci U S A; 2006 May; 103(18):7094-9. PubMed ID: 16641095
[TBL] [Abstract][Full Text] [Related]
5. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
Boltz VF; Bao Y; Lockman S; Halvas EK; Kearney MF; McIntyre JA; Schooley RT; Hughes MD; Coffin JM; Mellors JW;
J Infect Dis; 2014 Mar; 209(5):703-10. PubMed ID: 24443547
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
[TBL] [Abstract][Full Text] [Related]
7. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
Wagner TA; Kress CM; Beck I; Techapornroong M; Wittayapraparat P; Tansuphasawasdikul S; Jourdain G; Ngo-Giang-Huong N; Lallemant M; Frenkel LM
J Clin Microbiol; 2010 May; 48(5):1555-61. PubMed ID: 20181911
[TBL] [Abstract][Full Text] [Related]
8. Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.
Lehman DA; Wamalwa DC; McCoy CO; Matsen FA; Langat A; Chohan BH; Benki-Nugent S; Custers-Allen R; Bushman FD; John-Stewart GC; Overbaugh J
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):225-33. PubMed ID: 22395670
[TBL] [Abstract][Full Text] [Related]
9. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
Jourdain G; Wagner TA; Ngo-Giang-Huong N; Sirirungsi W; Klinbuayaem V; Fregonese F; Nantasen I; Techapornroong M; Halue G; Nilmanat A; Wittayapraparat P; Chalermpolprapa V; Pathipvanich P; Yuthavisuthi P; Frenkel LM; Lallemant M;
Clin Infect Dis; 2010 May; 50(10):1397-404. PubMed ID: 20377404
[TBL] [Abstract][Full Text] [Related]
10. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
Martinson NA; Morris L; Johnson J; Gray GE; Pillay V; Ledwaba J; Dhlamini P; Cohen S; Puren A; Steyn J; Heneine W; McIntyre JA
AIDS; 2009 Apr; 23(7):809-16. PubMed ID: 19287298
[TBL] [Abstract][Full Text] [Related]
11. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
Lehman DA; Chung MH; Mabuka JM; John-Stewart GC; Kiarie J; Kinuthia J; Overbaugh J
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):522-9. PubMed ID: 19502990
[TBL] [Abstract][Full Text] [Related]
12. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS
AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
[TBL] [Abstract][Full Text] [Related]
13. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.
Boltz VF; Zheng Y; Lockman S; Hong F; Halvas EK; McIntyre J; Currier JS; Chibowa MC; Kanyama C; Nair A; Owino-Ong'or W; Hughes M; Coffin JM; Mellors JW
Proc Natl Acad Sci U S A; 2011 May; 108(22):9202-7. PubMed ID: 21576473
[TBL] [Abstract][Full Text] [Related]
14. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.
Hauser A; Mugenyi K; Kabasinguzi R; Bluethgen K; Kuecherer C; Harms G; Kunz A
Antimicrob Agents Chemother; 2009 Jul; 53(7):2965-73. PubMed ID: 19433556
[TBL] [Abstract][Full Text] [Related]
15. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
[TBL] [Abstract][Full Text] [Related]
16. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Eshleman SH; Mracna M; Guay LA; Deseyve M; Cunningham S; Mirochnick M; Musoke P; Fleming T; Glenn Fowler M; Mofenson LM; Mmiro F; Jackson JB
AIDS; 2001 Oct; 15(15):1951-7. PubMed ID: 11600822
[TBL] [Abstract][Full Text] [Related]
17. Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.
Rowley CF; Boutwell CL; Lockman S; Essex M
J Virol Methods; 2008 Apr; 149(1):69-75. PubMed ID: 18295909
[TBL] [Abstract][Full Text] [Related]
18. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
Jones D; Parkin N; Hudelson SE; Guay LA; Musoke P; Mmiro F; Jackson JB; Eshleman SH
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):319-24. PubMed ID: 15943576
[TBL] [Abstract][Full Text] [Related]
19. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Samuel R; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
[TBL] [Abstract][Full Text] [Related]
20. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
Coovadia A; Hunt G; Abrams EJ; Sherman G; Meyers T; Barry G; Malan E; Marais B; Stehlau R; Ledwaba J; Hammer SM; Morris L; Kuhn L
Clin Infect Dis; 2009 Feb; 48(4):462-72. PubMed ID: 19133804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
